Member Info for gixer

I wasn't only referring to 2025 but also to the health functions. At the moment there is a list of 24 health functions that are allowed in China. Hopefully "helps maintain normal platelet aggregation function and is beneficial to the healthy function of blood flow" that By-Health has applied for will be # 25.

:)

25 is the magic number.

"In addition, By-Health is also actively developing cutting-edge fields such as microecology and cardiovascular health, and developing new product categories with strong functions to meet the growing health needs of consumers. The company's eight-year research project on levofloxacin" (Fruitflow) "not only fills the gap in related fields in China, but also opens up new growth points for the company."

https://news.sohu.com/a/833793434_121645878

https://news-sohu-com.translate.goog/a/833793434_121645878?_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=wapp

From Serbia Biocard

https://www.apotekamilica.rs/product/biocard-30-kapsula

"5 Best Pre-workouts in 2025"

Don't know how they know yet but Optimum Nutrition - Platinum Pump got "Best Stim-free"

https://comparetheproduct.com/5-best-pre-workouts-in-2025

"National Phase: after the end of the PCT procedure, usually at 30 months from the earliest filing date of your initial application, from which you claim priority, you start to pursue the grant of your patents directly before the national (or regional) patent Offices of the countries in which you want to obtain them."

Priority date was 7 June 2022

So we (Provexis) has picked Australia and New Zealand first.

Can we assume there is interest from here?

Gut microbiota patent now applied for in New Zealand (Publication Date 29.11.2024)

https://patentscope.wipo.int/search/en/detail.jsf?docId=NZ443385886&_cid=P12-M4CCK2-01446-1

and Australia (5.12.2024)

https://worldwide.espacenet.com/publicationDetails/biblio?DB=EPODOC&II=0&ND=3&adjacent=true&locale=en_EP&FT=D&date=20241205&CC=AU&NR=2023282466A1&KC=A1

Since its quiet.

I see DSM's Bovaer is getting bad press atm.

Agree Skibba,

Be interesting to see where Coltman goes to after this.

To be fair, neither you or I know exactly how many hours IF puts in per day.

You may not but I believe what Buck has said.

Rpg7 Re: "I wonder what constitutes a days work in' Provexis land'?"

It was reported that a similar question was asked at the AGM to which the Chairman replied that the CEO "was putting in way in excess of the average daily shift"

Don't worry, you will get at least one more before the end of the year :)

Https://baijiahao.baidu.com/s?id=1815982388363852087&wfr=spider&for=pc

https://baijiahao-baidu-com.translate.goog/s?id=1815982388363852087&wfr=spider&for=pc&_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=wapp

Well maybe not that new but I don't remember it being highlighted before.

Brain Flow Complex.

https://www.sunday.at/brain-flow-komplex-kapseln.html

That makes it the third product in this companies list.

If required, "previous players" or "rights issue" would be fine by me. Just not Primary Bid again please.

Having a look....

"no mans land" seems to be getting bigger pretty quickly.

https://www.grandviewresearch.com/horizon/outlook/cardiovascular-health-supplements-market/china

So, after the recent study/publication from Chettinad Academy that Provexis funded along with Chettinad Academy

https://www.sciencedirect.com/science/article/pii/S0753332224014938?fbclid=IwY2xjawGPJRpleHRuA2FlbQIxMQABHeb7gCfnwHnpxhZoEbG341kp1UixCFwjxcj8ga4oan5SWAlSqVTgS59S4A_aem_X6UL7QTWdbvfKh8Nu4oggQ

they are discussing further research collaborations????

Not to mention touring the Cancer institute......

Https://www.facebook.com/story.php?story_fbid=970273258451315&id=100064059486162&rdid=SgaazHyOWni9zQcc

"We had the immense honor of welcoming Professor Asim K. Dutta Roy from the University of Oslo to the Chettinad Academy of Research and Education on October 28-29, 2024! His visit included insightful guest lectures for our undergraduate and postgraduate students, engaging discussions on research collaborations, and interactions with our faculty. We explored potential PhD opportunities in Europe and shared valuable insights on the cardio protective effects of Fruitflow in cardiovascular diseases. Professor Dutta Roy also toured our Cancer Institute, learning about innovative cancer treatment techniques. His expertise and guidance have greatly enriched our academic community!"

This article is about the growth of the VDS in China but explains how B-H is struggling a bit at the moment and what their plans are to reverse the downturn in their revenue.

Amongst other thing Fruitflow will play its part.

"we need to attack strongly, expand market share and become a category leader; third, around the development of new functional categories, we must "march quickly" to take the lead in occupying no-man's land."

"By-Health has also laid out frontier areas such as microecology and cardiovascular health, and developed new categories with strong functions. For example, it took 8 years to study the function of maintaining normal platelet aggregation with levofloxacin, which is known as the "natural aspirin", and completed the experimental verification of the effect of By-Health's new levofloxacin tablets on the blood flow health of Chinese people, filling the domestic gap, and took the lead in submitting new function declaration and product registration applications."

https://www.tmtpost.com/7321688.html

https://www-tmtpost-com.translate.goog/7321688.html?_x_tr_sl=auto&_x_tr_tl=en&_x_tr_hl=en&_x_tr_pto=wapp

From the results 30-9-2024

"The Company and DSM have been in negotiations around the inventory transfer throughout the course of 2023 and 2024, and the Company expects to be able to conclude these further negotiations in the coming months. The amount of stock which the Company will finally elect to purchase from DSM remains uncertain, and it will ultimately depend on (i) the best before dates of this inventory, (ii) recent stability data which has confirmed that the best before dates of the inventory can be extended, (iii) estimated customer demand in 2024/25 and beyond, (iv) the comparative costs and timing of a potential production run for a new batch of material and (v) the Company's financial resources at that time."